Nurix Therapeutics Statistics Share Statistics Nurix Therapeutics has 76.45M
shares outstanding. The number of shares has increased by 18.36%
in one year.
Shares Outstanding 76.45M Shares Change (YoY) 18.36% Shares Change (QoQ) 0.46% Owned by Institutions (%) 99.99% Shares Floating 74.9M Failed to Deliver (FTD) Shares 99 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 13.95M, so 18.24% of the outstanding
shares have been sold short.
Short Interest 13.95M Short % of Shares Out 18.24% Short % of Float 21.43% Short Ratio (days to cover) 11.83
Valuation Ratios The PE ratio is -7.67 and the forward
PE ratio is -2.77.
Nurix Therapeutics's PEG ratio is
-0.88.
PE Ratio -7.67 Forward PE -2.77 PS Ratio 27.21 Forward PS 11.1 PB Ratio 2.82 P/FCF Ratio -8.16 PEG Ratio -0.88
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Nurix Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.46,
with a Debt / Equity ratio of 0.05.
Current Ratio 6.46 Quick Ratio 6.46 Debt / Equity 0.05 Debt / EBITDA -0.14 Debt / FCF -0.16 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $190.73K Profits Per Employee $-676.81K Employee Count 286 Asset Turnover 0.08 Inventory Turnover n/a
Taxes Income Tax 270K Effective Tax Rate -0.14%
Stock Price Statistics The stock price has increased by -54.55% in the
last 52 weeks. The beta is 2.15, so Nurix Therapeutics's
price volatility has been higher than the market average.
Beta 2.15 52-Week Price Change -54.55% 50-Day Moving Average 11.8 200-Day Moving Average 15.72 Relative Strength Index (RSI) 30.98 Average Volume (20 Days) 849,966
Income Statement In the last 12 months, Nurix Therapeutics had revenue of 54.55M
and earned -193.57M
in profits. Earnings per share was -2.88.
Revenue 54.55M Gross Profit 38.12M Operating Income -213.03M Net Income -193.57M EBITDA -196.6M EBIT -213.03M Earnings Per Share (EPS) -2.88
Full Income Statement Balance Sheet The company has 110M in cash and 28.3M in
debt, giving a net cash position of 81.69M.
Cash & Cash Equivalents 110M Total Debt 28.3M Net Cash 81.69M Retained Earnings -738.77M Total Assets 591.55M Working Capital 439.72M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -172.58M
and capital expenditures -9.27M, giving a free cash flow of -181.86M.
Operating Cash Flow -172.58M Capital Expenditures -9.27M Free Cash Flow -181.86M FCF Per Share -2.71
Full Cash Flow Statement Margins Gross margin is 69.88%, with operating and profit margins of -390.52% and -354.85%.
Gross Margin 69.88% Operating Margin -390.52% Pretax Margin -354.36% Profit Margin -354.85% EBITDA Margin -360.41% EBIT Margin -390.52% FCF Margin -333.38%
